0.77
+0.0064(+0.83%)
Currency In USD
Address
263 Great Valley Parkway
Malvern, PA 19355
United States of America
Phone
484 328 4701
Website
Sector
Healthcare
Industry
Biotechnology
Employees
65
First IPO Date
December 03, 2014
| Name | Title | Pay | Year Born |
| Dr. Shankar Musunuri M.B.A., Ph.D. | Co-Founder, Chief Executive Officer & Chairman | 864,246 | 1964 |
| Dr. Uday B. Kompella Ph.D. | Co-founder & Independent Director | 60,000 | 1967 |
| Dr. Arun Upadhyay Ph.D. | Chief Scientific Officer and Head of Research & Development | 598,056 | 1983 |
| Ms. Tiffany J. Hamilton M.B.A. | AVice President & Head of Corporate Communications | 0 | N/A |
| Ms. Jyothy Pillai M.S. | Vice President & Head of Regulatory & Quality | 0 | N/A |
| John Kouch J.D. | General Counsel | 0 | N/A |
| Mr. Ramesh Ramachandran C.M.A., CPA, M.B.A. | Principal Financial Officer & Principal Accounting Officer | 0 | N/A |
| Ms. Kristen Craft | Head of People & Culture | 0 | N/A |
| Dr. Huma Qamar CMI, M.D., M.P.H. | Chief Medical Officer | 0 | 1984 |
| Mr. Michael Shine M.B.A. | Senior Vice President of Commercial | 0 | N/A |
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.